摘要
本研究的目的是探討包含長度、直徑、線肋溝槽寬度比之血管支架設計參數，在不同壓力負載下進行模擬後，求得受到反覆血壓之血管支架允許壽命。 首先參考Palmaz-Schatz血管支架並使用Pro/E Wildfire繪圖軟體繪出Diamond 型血管支架實體圖，再以ANSYS11.0進行後續分析，然後於靜態下考慮血管支架的材料非線性性質，並透過施加氣球膨脹壓力與氣球洩壓來產生塑性變形與殘留應力；之後再施加平均動脈壓來進行應力分析，求出不同支架設計的最大應力與分佈。 在動態分析前先進行模態分析，以確認心跳頻率是否接近血管支架的基本自然頻率，而造成共振現象。其次於動態響應之暫態模擬中施加氣球膨脹、洩壓預應力，以及高血壓前期病變之血壓負載來模擬各尺寸支架的受力情況。最後應用暫態模擬的結果進行應力壽命疲勞分析，可產生不同反覆血壓負載與不同支架設計之疲勞週期。研究結果除了能評估血管支架是否有足夠安全性外，也能區別出未來血管支架臨床測試的優先次序類型。
並列摘要
The purpose of this study is to get the allowed lifetime of vascular stents, which undergone blood pressure repeatedly, through simulations under different pressures on various designed parameters including stent length, diameter, strut-to-slot width ratio. First, this study built up 3D geometrical models of Diamond-shaped stent Palmaz-Schatz vascular stent by Pro/E Wildfire, followed by analysis utilizing ANSYS 11.0. Then, considering the non-linear property of the stent material, this study performed static analysis using inflated pressure and deflated pressure of the balloon to produce plastic deformation and residual stress. Lastly, applying mean blood pressure, this study performed the stress analysis again and acquired the greatest stress and stress distribution from the designed stents. Before the dynamic analysis, this study carried out a modal analysis to confirm whether the heartbeat frequency was close to fundamental natural frequency of stents and resulted in resonance. In addition, this study performed transient analysis of dynamic response in the stent models, which were undergone the inflation and deflation prestresses of the balloon and then suffered the the blood pressure loads of pre-hypertensive diseases to simulate the stress situations of designed stent. Finally, this study used transient analytic results to proceed to the S-N fatigue analysis to obtain the fatigue life cycles of various designed stent through different repeated blood pressure loads. The result of this study not only evaluates the security efficiency of the vascular stents, and can also distinguish the priority order of types for future clinical trials.